Quantifying the Tumor Sink Effect in [ 177 Lu] LuPSMA617 Therapy: Implications for Personalized Dosimetry (EANM 2026) - Sep 29, 2026 - Abstract #EPS-005; Pres time: Oct 18, 2026; 08:00 AM - 09:30 AM; Location: Hall G2; "This study provides quantitative evidence of a clinically relevant tumor sink effect in [177Lu]LuPSMA617 therapy. High tumor burden significantly reduces normal-organ uptake and lowers absorbed doses, highlighting the necessity of incorporating tumor burden into personalized dosimetry and activity planning. While PBPK modeling and pre-therapy PET are reliable tools for dose prediction, their interpretation must account for sink-driven biodistribution changes to optimize PSMA-RLT outcomes."
Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
S. Bagheri 1; A. Ebrahimifard 1; D. Librizzi 2; F. Eilsberger 1; M. Luster 1; B. Hooshyar Yousefi 1
|